Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer

StatusNot Yet Recruiting
PhaseEarly Phase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 3 of 3 changed
See other at-risk trials from Lumina Pharmaceuticals Inc

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv3
  2. Primary endpoint(s) modifiedv2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Lumina Pharmaceuticals Inc
1 trial monitored
See 1 trial at risk
Breast Cancer
5,455 trials monitored
See 306 trials at risk
Lung Cancer
4,798 trials monitored
See 270 trials at risk
Colorectal Cancer
3,405 trials monitored
See 162 trials at risk
and 12 more diseases
The objective of this study is to assess two novel positron emission tomography (PET) radiotracers, \[64Cu\]CM500 and \[68Ga\]CM500, for Positron Emission Tomography-Magnetic Resonance Imaging (PET-MR) and Positron Emission Tomography / Computed Tomography (PET-CT) imaging of solid tumors. These tracers have the potential to detect solid tumors throughout the body and may enable doctors to identify smaller tumors than conventional imaging techniques.
Trial Details
NCT Number NCT07781852
Lead Sponsor Lumina Pharmaceuticals Inc
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC), Pharynx Cancer +8 more
Related terms Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Esophageal Neoplasms, Glioblastoma, Glioma, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Mouth Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Pharyngeal Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Urinary Bladder Neoplasms
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov